Literature DB >> 7809128

Oncogenic capacity of the E2F1 gene.

D G Johnson1, W D Cress, L Jakoi, J R Nevins.   

Abstract

Previous experiments have identified the E2F transcription factor as a potential downstream target for the action of cellular regulatory activities, such as the Rb tumor suppressor protein, that control cell growth and that, when altered, contribute to the development of human tumors. In light of these findings, we have assayed the ability of the E2F1 and DP1 genes, which encode heterodimeric partners that together create E2F activity, to act in an oncogenic fashion. We find that E2F1, particularly in combination with the DP1 product, cooperates with an activated ras oncogene to induce the formation of morphologically transformed foci in primary rat embryo fibroblast cultures. In addition, an E2F1 chimeric protein, in which sequences involved in Rb binding have been replaced with the herpesvirus VP16 activation domain, exhibits increased transformation activity. Cells transfected with E2F1 and DP1 or the E2F1-VP16 chimera form colonies in soft agar and induce tumor formation in nude mice. We conclude that deregulated E2F1 expression and function can have oncogenic consequences.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809128      PMCID: PMC45532          DOI: 10.1073/pnas.91.26.12823

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  The E2F transcription factor is a cellular target for the RB protein.

Authors:  S P Chellappan; S Hiebert; M Mudryj; J M Horowitz; J R Nevins
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

2.  Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation.

Authors:  S Bagchi; P Raychaudhuri; J R Nevins
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

3.  Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression.

Authors:  S J Triezenberg; R C Kingsbury; S L McKnight
Journal:  Genes Dev       Date:  1988-06       Impact factor: 11.361

4.  Interacting domains of E2F1, DP1, and the adenovirus E4 protein.

Authors:  W D Cress; J R Nevins
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Malignant transformation of early passage rodent cells by a single mutated human oncogene.

Authors:  D A Spandidos; N M Wilkie
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

6.  Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture.

Authors:  H E Ruley
Journal:  Nature       Date:  1983 Aug 18-24       Impact factor: 49.962

7.  Use of nude mice for tumorigenicity testing and mass propagation.

Authors:  S Shin
Journal:  Methods Enzymol       Date:  1979       Impact factor: 1.600

8.  Complete transformation by adenovirus 2 requires both E1A proteins.

Authors:  C Montell; G Courtois; C Eng; A Berk
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

9.  A cell cycle regulator potentially involved in genesis of many tumor types.

Authors:  A Kamb; N A Gruis; J Weaver-Feldhaus; Q Liu; K Harshman; S V Tavtigian; E Stockert; R S Day; B E Johnson; M H Skolnick
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

10.  A novel cyclin encoded by a bcl1-linked candidate oncogene.

Authors:  T Motokura; T Bloom; H G Kim; H Jüppner; J V Ruderman; H M Kronenberg; A Arnold
Journal:  Nature       Date:  1991-04-11       Impact factor: 49.962

View more
  65 in total

1.  Regulation of endogenous E2F1 stability by the retinoblastoma family proteins.

Authors:  F Martelli; D M Livingston
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  E2F1 and E2F2 determine thresholds for antigen-induced T-cell proliferation and suppress tumorigenesis.

Authors:  J W Zhu; S J Field; L Gore; M Thompson; H Yang; Y Fujiwara; R D Cardiff; M Greenberg; S H Orkin; J DeGregori
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Deregulation of Rb-E2F1 axis causes chromosomal instability by engaging the transactivation function of Cdc20-anaphase-promoting complex/cyclosome.

Authors:  Somsubhra Nath; Abhishek Chowdhury; Sanjib Dey; Anirban Roychoudhury; Abira Ganguly; Dibyendu Bhattacharyya; Susanta Roychoudhury
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

4.  PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

Authors:  S Altiok; M Xu; B M Spiegelman
Journal:  Genes Dev       Date:  1997-08-01       Impact factor: 11.361

5.  RB and hbrm cooperate to repress the activation functions of E2F1.

Authors:  D Trouche; C Le Chalony; C Muchardt; M Yaniv; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription.

Authors:  Paloma H Giangrande; Wencheng Zhu; Susanne Schlisio; Xin Sun; Seiichi Mori; Stefan Gaubatz; Joseph R Nevins
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

7.  CtIP activates its own and cyclin D1 promoters via the E2F/RB pathway during G1/S progression.

Authors:  Feng Liu; Wen-Hwa Lee
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 8.  Cardiac myocyte cell cycle control in development, disease, and regeneration.

Authors:  Preeti Ahuja; Patima Sdek; W Robb MacLellan
Journal:  Physiol Rev       Date:  2007-04       Impact factor: 37.312

9.  Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.

Authors:  W Li; J Fan; D Hochhauser; D Banerjee; Z Zielinski; A Almasan; Y Yin; R Kelly; G M Wahl; J R Bertino
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

10.  Functional interaction between DP-1 and p53.

Authors:  T S Sørensen; R Girling; C W Lee; J Gannon; L R Bandara; N B La Thangue
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.